Real-time Adaptation to Changes in Insulin Sensitivity
NCT01261052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2012-12-03
Summary
The purpose of this research study is to test an automated blood glucose control system that includes a new component designed to adapt to stress. The importance of this component is that when Type 1 Diabetics are stressed (for example, from illness or infection), their body is resistant to the effects of insulin. The investigators will be adjusting their blood glucose using insulin and glucagon and making their body less sensitive to insulin with a steroid, hydrocortisone. Insulin is a hormone that lowers blood glucose. Glucagon raises blood glucose when it is low. Both are natural hormones made by people without diabetes. Hydrocortisone is a steroid that will increase their blood glucose temporarily and will be given every 4 hours. All subjects will participate in two 33 hour experiments. One experiment will use the adaptive version of the sensor-based glucose control system. The other study will use the original version of the control system, without the adaptive component, for the first 13 hours. Then, the adaptive component will be added to the glucose control system for the remaining 20 hours of the study. Our primary goal is to assess the effectiveness of the adaptive component to control glucose levels in the presence of steroid-induced insulin resistance in persons with Type 1 Diabetes Mellitus.
Conditions
- Type 1 Diabetes Mellitus
Interventions
- DEVICE
-
The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm
The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The "fading memory" designation refers to weighting recent errors more heavily than remote errors. The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin.
- DEVICE
-
The Adaptive Proportional Derivative Algorithm
The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The "fading memory" designation refers to weighting recent errors more heavily than remote errors. The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin.
Sponsors & Collaborators
-
Juvenile Diabetes Research Foundation
collaborator OTHER -
Legacy Health System
lead OTHER
Principal Investigators
-
W K Ward, MD · Legacy Health Research
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 21 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-11-30
- Primary Completion
- 2011-04-30
- Completion
- 2011-04-30
Countries
- United States
Study Locations
More Related Trials
-
A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users
NCT04123054 ·Status: COMPLETED ·Phase: NA
-
Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D
NCT04335513 ·Status: UNKNOWN ·Phase: NA
-
DreaMed Advisor Pro System in Subjects With Type 1 Diabetes Treated With MDI Therapy
NCT04043260 ·Status: COMPLETED ·Phase: NA
-
The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes
NCT02660242 ·Status: COMPLETED ·Phase: PHASE2
-
Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
NCT06609356 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes
NCT04614168 ·Status: COMPLETED ·Phase: NA
-
Prospective Randomized Clinical Trial Assessing the Short Term Clinical Impact of Continuous vs Flash Glucose Monitoring in Children, Adolescents and Young Adults With Type 1 Diabetes
NCT04249102 ·Status: UNKNOWN ·Phase: NA
-
Exercise-Induced Hypoglycemia Prevention in Adults With Type 1 Diabetes Using an Artificial Pancreas
NCT03859401 ·Status: COMPLETED ·Phase: NA
-
A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults with Type-1 Diabetes Mellitus
NCT06097689 ·Status: COMPLETED ·Phase: NA
-
Tissue-Specific Metabolic Reprogramming in Diabetic Complications
NCT01823406 ·Status: COMPLETED ·Phase: NA
-
Assessment of a Decision Support Tool in Participants With Type 1 Diabetes
NCT04428645 ·Status: COMPLETED ·Phase: NA
-
Evaluation of a Decision Support System for People With Diabetes Who Use Multiple Daily Insulin Injections- Feasibility and Proof of Concept Studies
NCT04653961 ·Status: RECRUITING ·Phase: NA
-
Hybrid Closed Loop in High Risk Youth With Type 1 Diabetes
NCT04807374 ·Status: COMPLETED ·Phase: NA
-
The Steno Opti-Bolus-Timing Studies
NCT07021690 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia
NCT01919385 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes
NCT03307850 ·Status: COMPLETED ·Phase: NA
-
Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue for the Treatment of Type-1 Diabetic Patients
NCT00812591 ·Status: COMPLETED ·Phase: NA
-
The Efficacy of MDI Treatment With an Optimization Algorithm Adjusting Basal-Bolus Parameters in Children and Adolescents With Type 1 Diabetes at a Diabetes Camp
NCT03764280 ·Status: COMPLETED ·Phase: NA
-
Study of Insulin Therapy Augmented by Real Time Sensor IN Type 1 Children and Adolescents (START-IN!)
NCT00949221 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
NCT01769404 ·Status: COMPLETED ·Phase: PHASE1
-
Need-driven Treatment of the Patients With Type 1 Diabetes
NCT07128992 ·Status: NOT_YET_RECRUITING
-
Continue Glucose Monitoring Before Insulin Pump
NCT02813421 ·Status: COMPLETED ·Phase: NA
-
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
NCT00419562 ·Status: COMPLETED ·Phase: PHASE3
-
Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
NCT00357890 ·Status: COMPLETED ·Phase: NA
-
Impact of Functional Insulinotherapy on Blood Glucose Variability Indicators in Patients With Type 1 Diabetes
NCT00973492 ·Status: UNKNOWN